Influenza A/B vs RSV Rapid Tests: How Should Distributors Choose?

Influenza A/B and RSV rapid tests are core products for respiratory portfolios. Both targets have overlapping clinical presentations, and many distributors carry either single-analyte products, combination tests, or both. The selection depends on clinical workflow, intended user, specimen handling, seasonal demand and regulatory requirements in each market.

Understand the target and intended workflow

Influenza A/B rapid tests detect influenza type A and type B antigens, typically from nasopharyngeal swabs. RSV rapid tests detect respiratory syncytial virus antigen. Both are lateral flow immunoassays designed for point-of-care or near-patient testing.

Clinical guidelines may recommend rapid testing for specific populations, such as pediatric patients for RSV or elderly patients during influenza season. Distributors should understand whether the destination market prefers separate tests for each target or combination products that differentiate flu and RSV on the same device.

Compare users and settings

Rapid influenza and RSV tests may be used in hospitals, clinics, pharmacies, emergency departments, pediatric units or home settings, depending on the intended use and regulatory status. The intended user (healthcare professional or lay user) affects labeling, instructions, packaging and evidence requirements.

A distributor should confirm whether the product is intended for professional use only, whether self-test versions are available, and whether the destination country accepts the intended-use claims.

Review specimen and kit configuration

Most influenza and RSV rapid tests use nasopharyngeal or nasal swab specimens. The kit may include a swab, extraction tube, buffer and test device. Distributors should verify swab type, extraction procedure, buffer volume and instructions for sample handling.

For professional-use products, specimen collection may be performed by trained staff. For self-test products, clear pictorial instructions and simplified swabbing procedures become more important. The complete kit cost, including swab and buffer, should be compared rather than just the device price.

Plan for seasonal demand

Influenza and RSV have seasonal patterns that vary by geography. Northern hemisphere flu season typically peaks in winter, while RSV may have different timing in pediatric populations. Distributors should align inventory, lead times and reorder schedules with expected demand windows.

Building pre-season stock, confirming production capacity and establishing a repeat-order plan helps avoid shortages during peak demand. PRISES can discuss lead times and seasonal planning for respiratory rapid test products.

Make a product-specific decision

Product selection should be based on the specific SKU, not assumptions about the manufacturer's general portfolio. Distributors should request product-specific performance information, intended-use statements, labeling samples and regulatory status for the exact configuration and destination country.

A portfolio may include both single-analyte influenza A/B tests for high-volume screening and combination Flu/RSV tests for settings where both targets are clinically relevant. Each product should have its own documentation file.